Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
3.21
-0.07 (-2.13%)
Real-time:   3:24PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.15 - 3.30
52 week 1.09 - 3.65
Open 3.30
Vol / Avg. 297,932.00/1.21M
Mkt cap 422.27M
P/E     -
Div/yield     -
EPS -0.45
Shares 128.34M
Beta 1.83
Inst. own 50%
Aug 3, 2015
Q2 2015 Curis Inc Earnings Release (Estimated) Add to calendar
Jun 3, 2015
Curis Inc at Jefferies Global Healthcare Conference
May 27, 2015
Curis Inc Annual Shareholders Meeting
May 21, 2015
Curis Inc Annual Shareholders Meeting (Estimated)
May 7, 2015
Q1 2015 Curis Inc Earnings Release
May 7, 2015
Q1 2015 Curis Inc Earnings Call
May 6, 2015
Curis Inc at Deutsche Bank Health Care Conference - One-on-One Meetings
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1920.50% -190.27%
Operating margin -1870.65% -161.14%
EBITD margin - -159.57%
Return on average assets -140.44% -26.16%
Return on average equity -217.62% -49.97%
Employees 35 -
CDP Score - -

Address

4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. (Curis) is a biotechnology company. The Company is engaged in the development and commercialization drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Curis' product pipeline also includes CUDC-427, an orally available, small molecule antagonist of inhibitor of apoptosis (IAP) proteins. CUDC-907 is in Phase I clinical trial stage for the treatment of advanced lymphomas and multiple myeloma, and human epidermal growth factor receptor 2 (HER 2-), estrogen-receptor-positive (ER+) or progesterone-receptor-positive (PR+) breast cancer and NUT midline carcinoma. CUDC-427 is in Phase I clinical trial stage for the treatment of advanced solid tumor and lymphomas. The Company's PD-L1 antagonist and IRAK4 Inhibitor drug candidates are in preclinical stage of development.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Michael P. Gray Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jaye Viner M.D. Chief Medical Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 55
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 73
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
Marc Rubin M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters